Autoimmune diseases: Is there light at the end of this tunnel?
Autoimmune diseases, like Type 1 diabetes, celiac disease, inflammatory bowel disease and autoimmune liver disease, occur when the body’s immune system turns on itself. The only treatments that currently exist involve suppressing the entire immune system, which leaves patients vulnerable to other infections or even cancer. In this webinar, Dr. Pere Santamaria, MD, PhD, sheds light on his discovery: a precision nanomedicine called Navacims. Designed to trigger a naturally-occurring regulatory mechanism in the immune system to protect against autoimmune diseases, this innovation is taking the next step toward commercialization — thanks to a worldwide collaboration and licence agreement between Parvus Therapeutics, founded by Dr. Santamaria, and Genentech, a member of the Roche Group.
Watch the webinar to learn more about this potentially game-changing treatment for autoimmune disorders discovered by a UCalgary scholar.
Recorded on July 3, 2019
Dr. Pere Santamaria, MD, PhD, is the Julia McFarlane/Diabetes Canada Research Chair and a professor in the Department of Microbiology, Immunology and Infectious Diseases at UCalgary’s Cumming School of Medicine.